CellRight Technologies LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CellRight Technologies LLC
Device/Diagnostics Quarterly Deal-Making Statistics, Q3 2017
Third-quarter device financing at $2.38 billion – almost half of that amount from CooperSurgical's $1.1 billion bridge loan – was double the Q2 total, while device acquisitions showed a steep decrease at $3.38 billion versus Q2's $33.4 billion. Diagnostics fundraising also was up in the third quarter, reaching $2.4 billion (a 133% increase over Q2) mostly from Thermo Fisher Scientific's $1.5 billion follow-on offering, which accounted for 63% of the total. In line with the previous quarter's $1.7 billion in M&A, Q3 diagnostics acquisitions had an aggregate value of $1.8 billion, led by Konica Minolta's $1 billion buy of Ambry Genetics.
Tissue Regenix Completes Search For New CEO
Regenerative medicine firm Tissue Regenix has named Steve Couldwell as its new CEO, following the departure of Anthony Odell, who led the group for over a decade.
Change At Helm As Tissue Regenix Enters Next Growth Phase
Regenerative medicine firm Tissue Regenix is now seeking a new CEO following the departure of Anthony Odell. The change in leadership comes two months after the company made its maiden M&A deal, acquiring CellRight Technologies.
- Implantable Devices
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.